Skip to content

Based on Metabonomics Dryness Pathogen Type of OLP: a Dynamic Study

Based on Metabonomics Dryness Pathogen Type of Oral Lichen Planus of Dynamic

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02332486
Acronym
OLP
Enrollment
25
Registered
2015-01-06
Start date
2015-01-31
Completion date
Unknown
Last updated
2015-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Brief summary

Due to the change of life style, the incidence of oral cavity mucous membrane disease increased.In this study,been done a large number of pre-clinical practice and some experimental studies, based on the application of metabolomics technology to ultra-high liquid-mass spectrometry metabolomics analyzer as the core means, The metabolism of pattern recognition and combination of modern analytical techniques to measure blood and urine of patients with OLP-specific clearance of endogenous metabolites,and after the intervention of moss drink endogenous metabolites in the body as a whole group of. At the same time, the use of flow cytometry,,ELISA, immunohistochemistry and other modern technology, research OLP patients using clean moss drink before and after treatment of local lesions and peripheral blood CD4 +,CD8 + lymphocytes,Th1 cytokines (IFN-γ, TNF-α), Th2 cytokines (IL-4,10) the dynamic changes. From metabolomics, cellular immunology, inflammation mechanism perspective of local OLP lesions, peripheral blood and changes in endogenous metabolites in the process,,in-depth study of traditional Chinese medicine to drink clean moss multi-component multi-target treatment of this disease mechanism, is widely used in traditional Chinese medicine treatment of OLP provide a theoretical basis for the promotion of Chinese medicine Qingxian Yin in the oral mucosal disease in the application, effectively solve clinical practice problems.

Interventions

DRUGQingxuan Decoction

In Qingxuan Decoction, there are a bag of Chinese honeylocust spine,Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.

Sponsors

Heilongjiang University of Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* All patients with OLP . * TCM syndrome of OLP patients included is dryness pathogen type. * In the lesions of oral mucosa there are phanerous pearly white keratinization stripes, or patches, or phanerous erosion with the mucous membrane hyperemia. * OLP patients may accompany oral coarse discomfort or pain, red tongue, yellow dry or dry fur, dry mouth, bitter taste.

Exclusion criteria

* Patients with other established oral mucosal disease; * Patients accompanied by serious systemic diseases, eg damaged liver or kidney functions; Or other allergic diseases, eg rheumatic disease or cancer. * Patients using the antibiotic in the last one month or immunologic agents in the last three months. * Lichenoid reaction caused by drugs or the filling with silver and amalgam. * Patients with smoking or alcoholism in the last three months.

Design outcomes

Primary

MeasureTime frame
visualanalogue scaleevery week of eight weeks

Secondary

MeasureTime frameDescription
Cytokinesevery week of eight weeksIFN-γ, TNF-α, IL-4 and IL-10 of the blood cells of CD4+/CD8+ and Th1/Th2 will be tested by flow cytometry or ELISA.
Biomarkerevery week of eight weeksMetabolites profiles of individual in the intervention group will be analysed by PCA、OPLS-DA or UPLC-MS.

Contacts

Primary ContactYang Xu Yan, Doctor
444125750@qq.com+86 0451-82193038

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026